Aesthetic Insights™
In this issue

Galderma Advances Research on Menopause-Related Skin Changes

Galderma Restylane AIA feature GIF

Sponsored by Galderma

Menopause is widely recognized for its systemic effects, but its impact on the skin has received far less attention. Hormonal changes beginning in perimenopause can accelerate visible skin aging. Research cited by Galderma indicates that women may lose around 30% of their skin collagen within the first five years after menopause1. The growing recognition of those changes is raising a larger question for aesthetic medicine. Should menopausal status become a routine consideration in how practitioners assess patients, plan treatment, and evaluate outcomes?

Galderma has made menopause-related skin changes a focus of new research and education. The company’s global survey of more than 4,300 women identified a substantial information gap2. In response, Galderma is incorporating menopausal status into injectable aesthetics trials and supporting research in peri- and post-menopausal women.

The implications extend beyond any single product or modality, raising broader questions about how menopause should inform aesthetic care.

To discuss menopause-related skin changes, board-certified dermatologists Doris Day, M.D., FAAD, MA, and Sabrina Fabi, M.D., FAAD, FAACS3, joined Tara Capalbo, Vice President and General Manager, U.S. Aesthetics at Galderma, and Sophia Kajla, M.D., Galderma’s Vice President, U.S. Medical Affairs. Together, they examined how menopause may affect aesthetic treatment planning and what evidence is still needed to support more individualized care.


What happens to the skin during the menopausal transition, and how do these changes differ from normal chronological aging?

Sophia Kajla, M.D.: Menopause is not simply a marker of chronological aging; it is a hormonal transition that affects the structure and biology of the body, including the integrity of the skin. As hormone levels fluctuate and decline, collagen production decreases significantly. Research has shown an approximately 30% reduction in collagen within the first five years after menopause1. Clinically, that can manifest as loss of firmness and elasticity, more visible fine lines and wrinkles, and increased dryness — all of which affect overall skin quality.

That distinction is important for aesthetic practitioners. A woman may present with what appears to be aging, but there may be a significant overlap between chronological aging and hormonally driven changes associated with menopause.

Doris Day, M.D., FAAD, MA: Many of these skin changes are nonspecific, because you can see them in people who aren’t in menopause, but they tend to accelerate during menopause. The skin can go through something of a roller coaster. You may see breakouts, dry or itchy skin, thinning skin, and more rapid signs of aging. One of the most common things patients tell me is, ‘One day my skin just fell apart.’ You can also see hair thinning and changes in the skin on the body, which can become more crepey and itchy.

day doris hs 02

When you put all those signs together and ask about sleep, mood, memory, joint symptoms, and menstrual changes, you can begin to recognize that a patient may be in perimenopause. If we identify and address these changes earlier, we may be able to help patients age better.

Sabrina Fabi, M.D., FAAD, FAACS: Dryness is probably the number one complaint I see in women who are perimenopausal. They may also notice that treatments that worked very well for them in their 20s and 30s no longer seem to produce the same result. They may not look as dewy or glowing after a treatment and may perceive that as the treatment no longer working, when in fact their skin and hormonal environment have changed. Their skincare may also need to change. Products they tolerated or benefited from when they were younger may no longer be appropriate because the skin barrier has changed. That is one of the important differences we begin to see in this group.

Why have menopause-related skin changes remained underrecognized, and where are the biggest education gaps for patients and practitioners?

Tara Capalbo: Our patient base is predominantly female, and perimenopause and are life stages that affect a very large portion of that population. Historically, much of the attention around menopause has focused on symptoms such as hot flashes and sleep disruption, while the changes occurring in the skin have received much less attention. That led us to ask how well women understand what is happening to their skin and whether there is an opportunity to better educate and support them.

Galderma surveyed more than 4,300 women across five continents to better understand their experiences2. What became clear was that there is not only a treatment opportunity, but a significant information gap. Many women told us they wished they had understood earlier how perimenopause and menopause could affect their skin and what they might be able to do about those changes.

Dr. Day: I think part of the problem is that, historically, physicians received very little training about menopause in medical school. That is beginning to change, but many physicians simply were not taught to think about menopause as something they should actively assess and manage. There has also been a great deal of confusion surrounding hormone therapy. For years, physicians and patients heard very simplified messages about estrogen, cancer risk and safety, and those messages have been difficult to reverse. I went back and looked closely at the studies because I wanted to understand the data for myself, and it became clear to me that the risks and benefits are much more nuanced than the way they were often presented.

We now have better data, different formulations, and a better understanding of timing and patient selection. Yet, many women who may be appropriate candidates for hormone therapy remain afraid of it because cancer risk is what they remember most strongly. They may not make the same connection with osteoporosis, cardiovascular disease, or cognitive health. A large part of this is education, both for patients and for providers. It has taken time, but I am seeing more clinicians pay attention to the evidence and think more broadly about menopause than they did in the past.

Dr. Fabi: Perimenopause can be a moving target, and not every woman has the same hormonal profile. That is why the approach must be personalized, just as it is in aesthetic medicine generally. We don’t treat every face the same way, and we shouldn’t assume every woman going through perimenopause is experiencing the same hormonal changes. For some patients, that may mean referral for a broader hormonal evaluation. My average patient is about 42, and many women at that age don’t yet associate what they’re seeing in their skin with hormonal changes.

Should menopausal status become a routine part of the aesthetic consultation, and how should it influence treatment planning?

Dr. Day: Menopausal status should become a routine part of the consultation and treatment plan for women in certain age groups. It is part of my consultations now, but unfortunately, it still isn’t common practice as menopause has often been something women felt they simply had to power through. One of the challenges is that perimenopause can be a very long stage, and it is different for everyone. Some women can enter perimenopause in their mid- to late 30s, while others may not enter it until much later.

Dr. Fabi: I agree that menopausal status should become a routine part of the aesthetic consultation. The question is how quickly the field will move in that direction, but greater education is beginning to make a difference. In my own teaching, I make a point of encouraging fellows, residents, and other trainees to ask about menopausal status because hormonal changes can affect more than the skin alone. They can influence how a woman feels, how she perceives herself, and even how satisfied she is with a treatment.

fabi hs 03

That may also mean changing the frequency of aesthetic treatments or modifying the topical regimen as the skin changes. That is important because a patient may feel that a treatment is no longer working as well as it once did, when the treatment itself may not be the problem. Her skin, hormonal environment, and overall state may have changed. Recognizing that allows us to have a broader conversation and, when appropriate, refer her for additional evaluation rather than simply changing the aesthetic treatment.

Dr. Kajla: We’re looking at menopause as one part of a comprehensive patient assessment in Galderma clinical trials, alongside factors such as age, anatomy, and the other elements that influence treatment planning. One of the things we’re working with the physician community on is asking the right questions — for example, whether a patient has noticed a relatively rapid change in hydration or firmness that may be associated with the menopausal transition.

The goal is not to treat menopause with aesthetics. It is to understand the biological context behind the patient’s concerns and then determine how aesthetic interventions may appropriately address them. There is no one-size-fits-all approach for women going through menopause. The symptoms and changes can vary considerably, so the care must be individualized.

What roles do injectables, skincare, devices and combination or sequencing strategies play in addressing menopause-related skin changes?

Dr. Fabi: Once we understand the changes occurring in the skin, we can begin to address the specific problem.

We can also use a biostimulator, such as Sculptra®, to help the processes involved in maintaining collagen, elastin, and overall skin quality. We have evidence that these treatments can improve characteristics of the skin beyond simply restoring volume. That is why having multiple treatment options is important. Menopause-related skin changes are multifactorial, so it often isn’t a question of choosing one treatment. It is about identifying what has changed and then creating a treatment plan, or sequencing treatments, to address those different needs.

Dr. Day: The benefit of using multiple treatment options is that patients don’t look ‘done.’ There isn’t one treatment that solves every problem. Fillers can’t do everything, Sculptra can’t do everything, and devices can’t do everything. But when you layer treatments thoughtfully and develop a plan, you can address different aspects of aging while maintaining balance. I typically create a one-year plan for my patients and then reassess and update it each year. By creating a treatment plan or sequencing treatment plan, between devices, injectables, and neurotoxins, you can help patients age in a way that looks natural and authentic. It isn’t necessarily about looking younger; it’s about looking healthy and balanced.

Ms. Capalbo: One of the things we’re very proud of at Galderma is the breadth of the portfolio we bring to the table. We have Dysport® (abobotulinumtoxinA)*, a broad Restylane® HA filler family with different indications for different areas of the face, Sculptra as a biostimulatory treatment, and ALASTIN® skincare. That range allows providers to address different concerns. The important point is how these products can help create an individualized treatment for the patient.

A woman may be most concerned about laxity, while another may be focused on dryness, hydration, or changes in facial structure. Those concerns may call for very different approaches. The provider needs to think about what to treat first, what to add later, and how the different modalities can work together over time. That kind of personalization is where I think the field is increasingly headed.

* Indication: IDysport® (abobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults ˂65 years of age. Please read full Important Safety Information for Dysport, including Distant Spread of Toxin Effect Boxed Warning, at the end of this article.

What does earlier intervention realistically mean for women approaching menopause?

Dr. Day: At this stage, the skin is generally breaking down collagen faster than it is building it, so intervention is about being more protective and supportive. That starts with smart sun protection — not avoiding the sun entirely but being thoughtful about when you’re exposed and how you protect areas like the face, neck, and hands. It also means using treatments that help support collagen, choosing skincare that is less irritating, and maintaining hydration and barrier function as oil production and the skin microbiome begin to change. The goal isn’t to stop change, because the face and skeleton will continue to change with age. The goal is to help patients maintain healthy, balanced skin through those changes.

Dr. Fabi: I explain to patients that hormones are part of the biological environment in which skin cells function. We can use topicals, devices, and injectables to help fibroblasts and support collagen production, but the hormonal environment can influence how those cells respond. That becomes especially relevant because many aesthetic treatments rely, at least in part, on a controlled wound-healing response. As patients move through perimenopause and menopause, changes in healing capacity may affect how quickly they recover or how strongly they respond to treatments such as laser resurfacing.

capalbo hs 01

When I think about earlier intervention, I think about maintaining the skin in as healthy and responsive a state as possible before those changes become more advanced. It doesn’t mean treatment later in life won’t work, but some patients may require more treatment to achieve the same degree of improvement.

Ms. Capalbo: If a patient understands that collagen declines substantially during the first several years after menopause, the question becomes, what can she do earlier to help preserve skin quality and support the skin through that transition? That may include appropriate skincare, energy-based treatments, and injectable treatments, depending on the patient’s individual needs. The broader idea is to give women information earlier so they can have a more proactive conversation with their provider, rather than waiting until changes become more advanced.

Galderma is incorporating menopausal status into its injectable aesthetics clinical trials and supporting menopause-specific research. What could this research reveal about how women respond to treatment?

Dr. Fabi: One thing I commend Galderma for is that menopausal status is now being captured in its clinical research, along with factors such as how long a woman has been menopausal and whether she is using hormone replacement therapy. That gives us an opportunity to begin stratifying the data and looking for meaningful trends — how quickly patients respond to treatment, how durable the results are, and whether those outcomes differ according to menopausal status or hormone therapy use. Once we have enough of that information, we can begin to make more evidence-based recommendations about treatment protocols, including how much intervention may be needed and how frequently treatments should be performed.

Dr. Day: What I really appreciate is when aesthetic companies invest in generating data specifically around peri- and post-menopausal women. Galderma has been leading the way in that area, and other companies are beginning to follow. I’m just finishing a study with Galderma looking at Sculptra treatment in the face in women who are peri- or post-menopausal. We’re also doing histology and biopsies, so we’ll be able to look more closely at what Sculptra may be doing in this group of women as they age. I give Galderma a lot of credit for making that kind of investment, especially with a product that is already approved. You don’t know what the data is going to show until you do the study, and they’ve been committed to finding out. I think that is very meaningful, and I was happy to participate.

What evidence is still missing, and where does the field go from here?

kajla hs 01

Dr. Kajla: We still need much more prospective clinical research specifically designed to understand women across the menopausal transition. We need to better understand how menopausal status influences skin quality, skin biology, patient needs, and treatment response. One of the challenges is that menopausal status has not been captured consistently as a variable in aesthetic research. Without that information, it is difficult to determine whether meaningful differences exist in how women respond to aesthetic treatments.

Over time, as that body of evidence grows, I think it will help clinicians move toward a more precise and individualized approach to treating women through this stage of life.

Dr. Day: We’re still in the infancy of understanding this, and we need many more studies. We need to better understand hormonal influences and how they affect the skin during perimenopause and menopause. I’m also involved in a study looking at topical estrogen, including epigenetic testing, to see what effect it may have on the skin. There is still so much we need to learn, especially as other factors such as GLP-1 use enter the picture and make the biology of aging even more complex.

We’re also beginning to understand more about proteomics and the many factors that influence how we age and our overall health. Ultimately, the answer is going to be multifactorial, so the treatment approach also has to be multilayered. We must look at internal factors, topical care, devices, home care, and lifestyle together. When those pieces are integrated, we have a much better chance of achieving good outcomes.


Galderma Supplement video 102226

Natural-Looking Results That Preserve Your Expressions

Dysport® is an neurotoxin treatment that smooths frown lines between the brows while preserving natural facial expressions. The video highlights results that may appear in as little as 24 hours, a 95% patient satisfaction rate, and the convenience of just two treatments per year.


References:

1 Affinito P, Palomba S, Sorrentino C, Di Carlo C, et al. Effects of postmenopausal hypoestrogenism on skin collagen. Maturitas 1999;33:239-47. 2. Brincat M, Moniz CJ, Studd JW, Darby A, et al. Long-term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985;92:256-9. 3. Thornton MJ. Estrogens and aging skin. Dermatoendocrinol 2013;5:264-70

2 Galderma. Data on file. Menopause Patient Survey.

3 Galderma Clinical Investigators


Dysport® Important Safety Information

Indication: Dysport® (abobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults ˂65 years of age.

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

CONTRAINDICATIONS
• Hypersensitivity to any botulinum toxin product or excipients
• Allergy to cow’s milk protein
• Infection at the proposed injection site(s)

WARNINGS AND PRECAUTIONS
• The potency Units of Dysport are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products.
• Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties.
• Recommended dose and frequency of administration should not be exceeded.
• Dry eye may occur with glabellar line treatment, if symptoms persist, consider referring patient to an ophthalmologist.
• Concomitant neuromuscular disorder may exacerbate clinical effects of treatment.

ADVERSE REACTIONS
• In clinical studies, the most frequently reported adverse events (≥2%) were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, nausea, and blood present in urine.

DRUG INTERACTIONS

• Concomitant use of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission or muscle relaxants, should be observed closely because effect of Dysport may be potentiated.
• Anticholinergic drugs may potentiate systemic anticholinergic effects.
• The effect of administering different botulinum neurotoxins during course of treatment with Dysport is unknown.

USE IN SPECIFIC POPULATIONS
• Dysport is not recommended for use in children or pregnant women.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information including Medication Guide at DysportUSA.com.

Sculptra® Important Safety Information

Sculptra® (injectable poly-L-lactic acid [PLLA-SCA]) is indicated for correction of shallow to deep nasolabial fold contour deficiencies, fine lines and wrinkles in the cheek region, and other facial wrinkles.

Sculptra should not be used by people that are allergic to any ingredient of the product or have a history of keloid formation or hypertrophic scarring. Safety has not been established in patients who are pregnant, lactating, breastfeeding, or under 18 years of age.

Sculptra has unique injection requirements and should only be used by a trained healthcare practitioner. Contour deficiencies should not be overcorrected because they are expected to gradually improve after treatment.

Sculptra should not be injected into the blood vessels as it may cause vascular occlusion, infarction, or embolic phenomena. Use at the site of skin sores, cysts, pimples, rashes, hives, or infection should be postponed until healing is complete. Sculptra should not be injected into the red area (vermillion) of the lip or in the peri-orbital area.

The most common side effects after initial treatment include injection site swelling, tenderness, redness, pain, bruising, bleeding, itching, and lumps. Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area. Larger lumps, some with delayed onset with or without inflammation or skin discoloration, have also been reported.

Sculptra is available only through a licensed practitioner. Complete Instructions for Use are available at www.SculptraUSA.com.

Restylane® Family Important Safety Information

The Restylane® family of products are indicated for patients over the age of 21, and includes Restylane®, Restylane®-L, Restylane® Lyft with Lidocaine, Restylane® Silk, Restylane® Kysse, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, and Restylane® Eyelight.

Restylane and Restylane-L are for mid-to-deep injection into the facial tissue for the correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds, and for lip enhancement.

Restylane Lyft with Lidocaine is for deep implantation into the facial tissue for the correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds, and for cheek augmentation and for the correction of age-related midface contour deficiencies. Restylane Lyft with Lidocaine is also indicated for injection into the dorsal hand to correct volume loss. Restylane Lyft with Lidocaine is also indicated for injection into the mid-to-deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild-to-moderate chin retrusion.

Restylane Silk is for lip augmentation and for correction of perioral wrinkles.

Restylane Kysse is for lip augmentation and for correction of upper perioral wrinkles.

Restylane Refyne is for mid-to-deep injection into the facial tissue for the correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds.

Restylane Defyne is for mid-to-deep injection into the facial tissue for the correction of moderate-to-severe, deep facial wrinkles and folds, such as nasolabial folds. Restylane Defyne is also indicated for injection into the mid-to-deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild-to-moderate chin retrusion.

Restylane Contour is for cheek augmentation and for the correction of midface contour deficiencies, and for correction of temple hollowing.

Restylane Eyelight is for the improvement of infraorbital hollowing.

Do not use if you have severe allergies that have required in-hospital treatment, are allergic to lidocaine or gram-positive bacterial proteins used to make hyaluronic acid, prone to bleeding, or have a bleeding disorder. The safety of use while pregnant or breastfeeding has not been studied. Tell your doctor if you are planning other cosmetic treatments (such as lasers and chemical peels) as there is a possible risk of inflammation at the injection site.

The most common side effects include swelling, redness, pain, bruising, headache, tenderness, lump formation, itching at the injection site, and impaired hand function (Restylane Lyft – hand injection). Tell your doctor if you’re taking medications that lower your body’s immune response or affect bleeding, such as aspirin or warfarin; these medications may increase the risk of bruising or bleeding at the gel injection site. Use at the site of skin sores, pimples, rashes, hives, cysts, or infection should be postponed until healing is complete.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers, and cases have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own. Serious but rare side effects include delayed-onset infections, recurrence of herpetic eruptions, superficial necrosis, and scarring at the injection site. The risk of unintentional injection into a blood vessel is small but can occur and could result in serious complications, which may be permanent including, vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. As with all skin injection procedures, there is a risk of infection.

To learn more about serious but rare side effects and full Important Safety Information, visit www.RestylaneUSA.com.

© 2026 Galderma Laboratories, L.P.

The Dysport trademark is used under license.

All trademarks are the property of their respective owners.

US-DYS-2600144

Please feel free to contact us directly at: info@miinews.com
© 2026 Medical Insight, Inc.